management program, only 14,3% patients with an indication for preventive treatment visited their GP and only 14% started with CV risk lowering drugs. This is mainly caused by the small percentage of high risk patients that contacted their GP. On the other hand, a high percentage reported the start of healthy lifestyle. These results underscore the need for a short-term follow-up, in close collaboration with primary care providers to ensure appropriate CV risk management. This is a future implementation project that will be initiated shortly. Background: RA patients have a higher risk for developing CV Diseases (e.g. IHD and stroke) than the general population.We reported previously (ACR, EULAR) the results CV risk in our patients treated with bDMARDs for 1& 2 years. Objectives: To assess the effect of bDMARDs treatment on 10-year CV disease risk in patients with RA after 36 months and evaluate the impact of their use on the incidence of CV events Methods: A cohort of RA patients was followed prospectively.Demographics, disease activity parameters, inflammatory markers, CV events, CVD 10 year risk assessment [Framingham Risk Score (FRS) ] were ascertained at the baseline and every six months, up to 36 months.Statistical analysis utilized SPSS (IBM version 24) software. Results: 321 patients were included, of those 270 patients were followed for three years. Eight BDMARDs were included evaluating their effect on disease activity and CV risk in 233 patients who continued on their prospective biologic for the three years. Significant overall reduction in disease activity in all groups was obtained as compared to baseline. The whole group DAS improved from 3.996 to 3.118.
The HAQ also improved significantly (1.201 to 0.857) and the CRP improved significantly (12.91 mg/L to 7.3). Overall, Total cholesterol (TC) changed from 5.195 mmol/L at baseline to 4.992 (P 0.001). High Density Lipoprotein Cholesterol (HDL-C) increased significantly at 36 months from 1.336 to 1.376. However, the Atherogenic Index (AI) for the whole cohort changed from 3.636 to 3.845. The overall 10 year risk of cardiovascular event increased from 12.878 to 13.8 The cohort included 321 patients. Eight bDMARDs were evaluated to assess their effect on disease activity and CVD risk. The outcomes in 233 patients who continued their prospective biologic for the three years were reported (table) . 77% were females, median RA duration was 11 ys. Significant reduction in disease activity in all groups was achieved vs. baseline. The DAS improved from 3.996 to 3.118, the HAQ improved significantly (1.201 to 0.857) and the CRP also improved significantly (12.91 mg/L to7.3). Overall, Total cholesterol (TC) changed from 5.195 mmol/L at baseline to 4.992 (P 0.001). High Density Lipoprotein Cholesterol (HDL-C) increased significantly at 36 months from 1.336 to 1.376. The Atherogenic Index (AI) for the cohort changed from 3.636 to 3.845. The overall 10 year risk of cardiovascular event increased from12.878 to 13.8. Background: Pain in patients with rheumatoid arthritis (RA) is the most common and troublesome symptom, occurs frequently in many sites in the muscularskeletal system, causes fatigue and functional impairment. The origin of pain in RA may be inflammatory and/or other, such as increased sensitivity to pain, fibromyalgia and osteoarthritis. Objectives: To study unacceptable pain in an inception cohort of patients with RA at 15 years follow-up Methods: This study concerns 477 patients from the BARFOT inception cohort study, consisting of 839 patients with early RA, who have passed the pre-defined 15 year follow-up visit. Unacceptable pain (UP) was defined as ≥40 mm on a continuous VAS pain scale of 100 mm with the ends "no pain" and "worst possible pain" (1). ADL-function was assessed by the HAQ test, physical function by the SOFI test and joint damage by the van der Heijde modified Sharp method. Remission was defined as DAS28 ≤2.6. The prevalence of UP over time as well as the relationship of UP with clinical variables were assessed. Baseline predictors of UP after 15 years were evaluated by logistic regression.
Results:
The mean baseline VAS pain was 45 mm, decreased after 6 months to 29 and remained after that fairly stable through the years ending in 31 at 15 years. UP followed a similar course with 56% of the patients at baseline, which decreased to 30% after 6 months and then behaved stable until 15 years, 34%. Seventy-seven per cent of the patients with UP were not in remission at 15 years, while 23% had UP in spite of being in remission.
Patients with UP who were in remission at the 15 years visit had higher mean age (p=0.004), ESR (p=0.001) and SOFI (p=0.001) than patients without UP.
Patients with UP who were not in remission at this point in time were more often women (0.008) and had more tender joints (p=0.001) than patients who did not have UP.
In both remission groups the mean DAS28, patient global assessment and HAQ were higher in patients with UP compared with patients without.
The means of the x-ray joint damage scores -total score, erosion and joint space narrowing scores -were very similar among patients with or without UP, statistically not significant. A logistic regression analysis of the ability of baseline variables to predict UP at 15 years was performed. It was shown that female gender and baseline pain independently predicted unacceptable pain at 15 years in patients not in remission while in patients in remission high age and ESR were independent predictors.
